Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1D | O15297 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2593873 | 0.83 | USP2 (0.32) | PPM1DCHRM2CHRM1CHRM3USP2 | |
| SCHEMBL875047 | 0.77 | CHRM2 (0.36) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL2119472 | 0.77 | CHRM2 (0.36) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL143218 | 0.76 | SMN1; SMN2 (0.33) | PPM1DCHRM2CHRM1CHRM3USP2 | |
| SCHEMBL15512775 | 0.76 | SMN1; SMN2 (0.33) | PPM1DCHRM2CHRM1CHRM3USP2 | |
| SCHEMBL29069175 | 0.73 | PPM1D (0.36) | PPM1DUSP2SMN1; SMN2 | |
| SCHEMBL29039969 | 0.73 | PPM1D (0.36) | PPM1DUSP2SMN1; SMN2 | |
| SCHEMBL29039966 | 0.73 | PPM1D (0.36) | PPM1DUSP2SMN1; SMN2 | |
| SCHEMBL377199 | 0.73 | PPM1D (0.36) | PPM1DUSP2SMN1; SMN2 | |
| SCHEMBL31105174 | 0.73 | PPM1D (0.36) | PPM1DUSP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095211-A1 | SUBSTITUTED PROLINE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095211-A1 | SUBSTITUTED PROLINE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | VIP, EIF2AK2, PREP | PPM1D 1670/4885CHRM2 4758/4885CHRM1 4719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.